Table A3.
Characteristics of the stage IV patients receiving first-line EGFR TKIs (only patients using Qiagen® EGFR RGQ PCR kit for their tissue samples).
| Characteristics | EGFR Mutation Test Results in Liquid/Tissue Biopsy | p Value | |
|---|---|---|---|
| Concordant (n = 26) | Discordant (n = 8) | ||
| Sex | 0.3784 | ||
| Female | 15 (58%) | 6 (75%) | |
| Male | 11 (42%) | 2 (25%) | |
| Age (year) | 64.3 ± 10.2 | 63.5 ± 10.5 | 0.8466 |
| Age: | 0.7016 | ||
| <65 years | 11 (42%) | 4 (50%) | |
| ≥65 years | 15 (58%) | 4 (50%) | |
| Performance status: | 0.3630 | ||
| ECOG 0–1 | 25 (96%) | 7 (88%) | |
| ECOG 2–4 | 1 (4%) | 1 (13%) | |
| Advanced primary tumor (T3–4) | 20 (77%) | 4 (50%) | 0.1439 |
| Lymph node involvement (N1–3) | 22 (85%) | 3 (38%) | 0.0083 |
| Metastasis (M1) | 26 (100%) | 8 (100%) | 0.0656 |
| Metastasis to: | |||
| Brain | 9 (35%) | 0 (0%) | 0.0523 |
| Lung | 9 (35%) | 4 (50%) | 0.4336 |
| Bone | 15 (58%) | 2 (25%) | 0.1058 |
| Pleural space | 15 (58%) | 5 (63%) | 0.8091 |
| Liver | 5 (19%) | 1 (13%) | 0.6623 |
| Pericardial space | 5 (19%) | 0 (0%) | 0.1793 |
| Adrenal gland | 4 (15%) | 1 (13%) | 0.8403 |
| Other site | 3 (12%) | 0 (0%) | 0.3143 |
| Mutation site: | |||
| Exon 18 | 1 (4%) | 0 (0%) | 0.5734 |
| Exon 19 | 13 (50%) | 6 (75%) | 0.2130 |
| Exon 21 | 12 (46%) | 2 (25%) | 0.2877 |
| TKI used: | 0.0312 | ||
| Gefitinib | 5 (19%) | 2 (25%) | |
| Erlotinib | 16 (62%) | 1 (13%) | |
| Afatinib | 5 (19%) | 5 (63%) | |
| Initial treatment response: | 0.3889 | ||
| Partial response (PR) | 14 (54%) | 4 (50%) | |
| Stable disease (SD) | 8 (31%) | 4 (50%) | |
| Progressive disease (PD) | 4 (15%) | 0 (0%) | |
| Objective response rate | 14 (54%) | 4 (50%) | 0.8488 |
| Disease control rate | 22 (85%) | 8 (100%) | 0.2376 |
Data were presented as mean ± standard deviation or number (percentage). Abbreviations: EGFR = epidermal growth factor receptor; ECOG = Eastern Cooperative Oncology Group; TKI = tyrosine kinase inhibitors.